Effects of 2 months of methylphenidate on energy expenditure in individuals with obesity: A randomized, double-blind, placebo-controlled pilot study

Physiol Rep. 2024 Jun;12(12):e16085. doi: 10.14814/phy2.16085.

Abstract

Methylphenidate (MPH) has been previously shown to increase resting energy expenditure (REE) in individuals of normal weight; however, the effects on individuals living with obesity are currently unknown. Ten individuals living with obesity were randomly assigned to undergo 60 days of MPH administration with a daily dose of 0.5 mg/kg body weight or a placebo control. REE was measured before and after the 60-day intervention. There was a trend toward significance for group × time interaction on REE (p = 0.082) with a large effect size (η2 = 0.331), with MPH administration increasing REE compared to a decrease in placebo control. Preliminary findings from this pilot study show that MPH has the potential to counter the adaptive thermogenic process commonly seen in weight loss. This is a unique finding among pharmacotherapies, as no approved obesity drugs measurably impact REE.

Keywords: adaptive thermogenesis; energy balance; energy expenditure; methylphenidate; obesity; weight loss.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Central Nervous System Stimulants / pharmacology
  • Central Nervous System Stimulants / therapeutic use
  • Double-Blind Method
  • Energy Metabolism* / drug effects
  • Female
  • Humans
  • Male
  • Methylphenidate* / pharmacology
  • Methylphenidate* / therapeutic use
  • Middle Aged
  • Obesity* / drug therapy
  • Obesity* / metabolism
  • Pilot Projects

Substances

  • Methylphenidate
  • Central Nervous System Stimulants